A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates

Rasool Sotudehmanesh, Reza Malekzadeh*, Ali Fazel, Sadegh Massarrat, Behrooz Ziad-Alizadeh, Mohammed Reza Eshraghian

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)

Abstract

Background and Aim: We sought to compare the efficacy and tolerability of an omeprazole/ clarithromycin/bismuth/tetracycline-based quadruple therapy to that of a ranitidine/metronidazole/ bismuth/tetracycline-based quadruple therapy of 2 or 3 weeks duration in a population with a high prevalence of metronidazole-resistant Helicobacter pylori and low triple therapy eradication rates.

Methods: Two hundred and twenty-one patients who presented endoscopically proven duodenal ulcers and a positive rapid urease test were randomized to receive either: (i) omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d., bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d (OCBT) for 2 weeks; (ii) ranitidine 300 mg b.i.d., metronidazole 500 mg b.i.d, bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (RMBT2) for 2 weeks; or (iii) ranitidine 300 mg b.i.d., metronidazole 500 mg b.i.d, bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (RMBT3) for 3 weeks. Patients were interviewed 2 weeks after the completion of therapy to review compliance and side-effects. Eradication of H. pylori was assessed 8 weeks after the completion of therapy with the use of a C-14-urea breath test.

Results: The per-protocol eradication rate was significantly higher with OCBT (88%) than RMBT2 (73%) or RMBT3 (71%) (P < 0.05). The intent-to-treat eradication rate was numerically higher with OCBT (80%) than RMBT2 (68%) or RMBT3 (68%), although this difference did not reach statistical significance (P = 0.09). Per-protocol or intent-to-treat eradication rates were similar with RMBT2 and RMBT3. There were significantly greater side-effects with the RMBT2 regimen.

Conclusions: The omeprazole/clarithromycin/bismuth/tetracycline-based quadruple therapy provides higher H. pylori eradication rates than the ranitidine/metronidazole/bismuth/tetracycline-based quadruple therapy when administered per protocol. The prolongation of the latter regimen from 2 to 3 weeks did not increase eradication rates. (C) 2001 Blackwell Science Asia Pry Ltd.

Original languageEnglish
Pages (from-to)264-268
Number of pages5
JournalJournal of gastroenterology and hepatology
Volume16
Issue number3
DOIs
Publication statusPublished - Mar-2001
Externally publishedYes

Keywords

  • Antibiotic resistance
  • Helicobacter pylori
  • Treatment
  • bismuth citrate
  • carbon 14
  • clarithromycin
  • metronidazole
  • omeprazole
  • ranitidine
  • tetracycline
  • urea
  • adult
  • antibiotic resistance
  • article
  • breath analysis
  • clinical protocol
  • clinical trial
  • controlled clinical trial
  • controlled study
  • drug efficacy
  • drug tolerability
  • duodenum ulcer
  • eradication therapy
  • female
  • gastrointestinal symptom
  • Gram negative infection
  • human
  • major clinical study
  • male
  • outcomes research
  • prevalence
  • priority journal
  • randomized controlled trial
  • xerostomia

Fingerprint

Dive into the research topics of 'A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates'. Together they form a unique fingerprint.

Cite this